Needham analyst Serge Belanger upgraded Amphastar (AMPH) to Buy from Hold with a $36 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Pharmaceuticals Enters Strategic Licensing Agreement
- Cautious Hold Rating on Amphastar Pharmaceuticals Amid Uncertain Product Approvals and Flat Revenue Growth
- Amphastar price target lowered to $25 from $30 at Piper Sandler
- Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights
- Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c